BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johansen JS, Krabbe KS, Møller K, Pedersen BK. Circulating YKL-40 levels during human endotoxaemia. Clin Exp Immunol. 2005;140:343-348. [PMID: 15807860 DOI: 10.1111/j.1365-2249.2005.02763.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Dela Cruz CS, Liu W, He CH, Jacoby A, Gornitzky A, Ma B, Flavell R, Lee CG, Elias JA. Chitinase 3-like-1 promotes Streptococcus pneumoniae killing and augments host tolerance to lung antibacterial responses. Cell Host Microbe. 2012;12:34-46. [PMID: 22817986 DOI: 10.1016/j.chom.2012.05.017] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 10.3] [Reference Citation Analysis]
2 Nielsen AR, Plomgaard P, Krabbe KS, Johansen JS, Pedersen BK. IL-6, but not TNF-α, increases plasma YKL-40 in human subjects. Cytokine. 2011;55:152-155. [PMID: 21478032 DOI: 10.1016/j.cyto.2011.03.014] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 6.0] [Reference Citation Analysis]
3 Marion CR, Wang J, Sharma L, Losier A, Lui W, Andrews N, Elias JA, Kazmierczak BI, Roy CR, Dela Cruz CS. Chitinase 3-Like 1 (Chil1) Regulates Survival and Macrophage-Mediated Interleukin-1β and Tumor Necrosis Factor Alpha during Pseudomonas aeruginosa Pneumonia. Infect Immun 2016;84:2094-104. [PMID: 27141083 DOI: 10.1128/IAI.00055-16] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
4 Halladin N, Ekeløf S, Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I. Lower limb ischaemia and reperfusion injury in healthy volunteers measured by oxidative and inflammatory biomarkers. Perfusion 2015;30:64-70. [DOI: 10.1177/0267659114530769] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Debray D, El Mourabit H, Merabtene F, Brot L, Ulveling D, Chrétien Y, Rainteau D, Moszer I, Wendum D, Sokol H, Housset C. Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice. Hepatol Commun 2018;2:1533-49. [PMID: 30556040 DOI: 10.1002/hep4.1266] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
6 Mathiasen AB, Henningsen KMA, Harutyunyan MJ, Mygind ND, Kastrup J. YKL-40: a new biomarker in cardiovascular disease? Biomarkers in Medicine 2010;4:591-600. [DOI: 10.2217/bmm.10.58] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
7 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
8 Bilim O, Takeishi Y, Kitahara T, Ishino M, Sasaki T, Suzuki S, Shishido T, Kubota I. Serum YKL-40 Predicts Adverse Clinical Outcomes in Patients With Chronic Heart Failure. Journal of Cardiac Failure 2010;16:873-9. [DOI: 10.1016/j.cardfail.2010.05.029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
9 Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82. [PMID: 19792974 DOI: 10.2217/fon.09.66] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 8.0] [Reference Citation Analysis]
10 Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I. Pronounced inflammatory response to endotoxaemia during nighttime: a randomised cross-over trial. PLoS One 2014;9:e87413. [PMID: 24475284 DOI: 10.1371/journal.pone.0087413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
11 Pizano-Martínez O, Yañez-Sánchez I, Alatorre-Carranza P, Miranda-Díaz A, Ortiz-Lazareno PC, García-Iglesias T, Daneri-Navarro A, Mercado MVD, Fafutis-Morris M, Delgado-Rizo V. YKL-40 expression in CD14+ liver cells in acute and chronic injury. World J Gastroenterol 2011; 17(33): 3830-3835 [PMID: 21987626 DOI: 10.3748/wjg.v17.i33.3830] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
12 Maddens B, Ghesquière B, Vanholder R, Demon D, Vanmassenhove J, Gevaert K, Meyer E. Chitinase-like proteins are candidate biomarkers for sepsis-induced acute kidney injury. Mol Cell Proteomics 2012;11:M111.013094. [PMID: 22233884 DOI: 10.1074/mcp.M111.013094] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
13 Frederiksen RF, Paspaliari DK, Larsen T, Storgaard BG, Larsen MH, Ingmer H, Palcic MM, Leisner JJ. Bacterial chitinases and chitin-binding proteins as virulence factors. Microbiology (Reading) 2013;159:833-47. [PMID: 23519157 DOI: 10.1099/mic.0.051839-0] [Cited by in Crossref: 111] [Cited by in F6Publishing: 104] [Article Influence: 13.9] [Reference Citation Analysis]
14 Mørup AM, Kornblit B, Johansen JS, Masmas TN, Madsen HO, Vindeløv L, Garred P. The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 2011;17:1299-307. [DOI: 10.1016/j.bbmt.2011.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
15 Johansen JS, Jensen BV, Roslind A, Price PA. Is YKL-40 a new therapeutic target in cancer? Expert Opinion on Therapeutic Targets 2007;11:219-34. [DOI: 10.1517/14728222.11.2.219] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
16 Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis. 2010;30:245-257. [PMID: 20665377 DOI: 10.1055/s-0030-1255354] [Cited by in Crossref: 778] [Cited by in F6Publishing: 760] [Article Influence: 70.7] [Reference Citation Analysis]
17 Coriati A, Massé C, Ménard A, Bouvet GF, Berthiaume Y. Neutrophils as a Potential Source of Chitinase-3-like Protein 1 in Cystic Fibrosis. Inflammation 2018;41:1631-9. [DOI: 10.1007/s10753-018-0806-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Coffman FD. Chitinase 3-Like-1 (CHI3L1): a putative disease marker at the interface of proteomics and glycomics. Crit Rev Clin Lab Sci. 2008;45:531-562. [PMID: 19003601 DOI: 10.1080/10408360802334743] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 6.4] [Reference Citation Analysis]
19 Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, Hirashiki K, Seki K, Shozu M. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20:71-77. [PMID: 18723551 DOI: 10.1093/annonc/mdn552] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
20 Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 2012;217:483-91. [DOI: 10.1016/j.imbio.2011.04.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
21 Kzhyshkowska J, Gratchev A, Goerdt S. Human Chitinases and Chitinase-Like Proteins as Indicators for Inflammation and Cancer. Biomark�Insights 2007;2:117727190700200. [DOI: 10.1177/117727190700200023] [Cited by in Crossref: 115] [Cited by in F6Publishing: 51] [Article Influence: 28.8] [Reference Citation Analysis]
22 Gerin F, Sener U, Erman H, Yilmaz A, Aydin B, Armutcu F, Gurel A. The Effects of Quercetin on Acute Lung Injury and Biomarkers of Inflammation and Oxidative Stress in the Rat Model of Sepsis. Inflammation 2016;39:700-5. [PMID: 26670180 DOI: 10.1007/s10753-015-0296-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
23 Schmalenberg M, Beaudoin C, Bulst L, Steubl D, Luppa PB. Magnetic bead fluorescent immunoassay for the rapid detection of the novel inflammation marker YKL40 at the point-of-care. Journal of Immunological Methods 2015;427:36-41. [DOI: 10.1016/j.jim.2015.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Johansen JS, Pedersen AN, Schroll M, Jørgensen T, Pedersen BK, Bruunsgaard H. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality. Clin Exp Immunol 2008;151:260-6. [PMID: 18070151 DOI: 10.1111/j.1365-2249.2007.03561.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
25 Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol 2009;511:159-84. [PMID: 19347297 DOI: 10.1007/978-1-59745-447-6_7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
26 Gao M, Wei Y, Xu Q, Ji R, Han Z, Jiang T. Elevated serum YKL-40 correlates with clinical characteristics in patients with polymyositis or dermatomyositis. Ann Clin Biochem 2019;56:95-9. [DOI: 10.1177/0004563218786979] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
27 Alikiaii B, Bagherniya M, Askari G, Johnston TP, Sahebkar A. The role of phytochemicals in sepsis: A mechanistic and therapeutic perspective. Biofactors 2021;47:19-40. [PMID: 33217777 DOI: 10.1002/biof.1694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Kim SH, Das K, Noreen S, Coffman F, Hameed M. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer. World J Surg Oncol 2007;5:17. [PMID: 17286869 DOI: 10.1186/1477-7819-5-17] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
29 Hattori N, Oda S, Sadahiro T, Nakamura M, Abe R, Shinozaki K, Nomura F, Tomonaga T, Matsushita K, Kodera Y, Sogawa K, Satoh M, Hirasawa H. YKL-40 identified by proteomic analysis as a biomarker of sepsis. Shock 2009;32:393-400. [PMID: 19197227 DOI: 10.1097/SHK.0b013e31819e2c0c] [Cited by in Crossref: 56] [Cited by in F6Publishing: 20] [Article Influence: 5.1] [Reference Citation Analysis]
30 Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, Friis T, Bindslev L, Haack-Sørensen M, Jørgensen E, Kastrup J. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J. 2008;42:295-302. [PMID: 18615353 DOI: 10.1080/14017430802220567] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 6.1] [Reference Citation Analysis]
31 Sutherland TE, Maizels RM, Allen JE. Chitinases and chitinase-like proteins: potential therapeutic targets for the treatment of T-helper type 2 allergies. Clin Exp Allergy. 2009;39:943-955. [PMID: 19400900 DOI: 10.1111/j.1365-2222.2009.03243.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 5.1] [Reference Citation Analysis]
32 Kjaergaard AD, Helby J, Johansen JS, Nordestgaard BG, Bojesen SE. Elevated plasma YKL-40 and risk of infectious disease: a prospective study of 94665 individuals from the general population. Clin Microbiol Infect 2020;26:1411.e1-9. [PMID: 31972315 DOI: 10.1016/j.cmi.2020.01.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Deng Y, Li G, Chang D, Su X. YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases. Clin Chim Acta 2020;511:40-6. [PMID: 33002471 DOI: 10.1016/j.cca.2020.09.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Fisher BJ, Kraskauskas D, Martin EJ, Farkas D, Puri P, Massey HD, Idowu MO, Brophy DF, Voelkel NF, Fowler AA. Attenuation of sepsis-induced organ injury in mice by vitamin C. JPEN J Parenter Enteral Nutr. 2014;38:825-839. [PMID: 23917525 DOI: 10.1177/0148607113497760] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
35 Hao H, Chen H, Xie L, Liu H, Wang D. LncRNA KCNQ1OT1 Promotes Proliferation, Invasion and Metastasis of Prostate Cancer by Regulating miR-211-5p/CHI3L1 Pathway. Onco Targets Ther 2021;14:1659-71. [PMID: 33688211 DOI: 10.2147/OTT.S288785] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Kornblit B, Hellemann D, Munthe-Fog L, Bonde J, Strøm JJ, Madsen HO, Johansen JS, Garred P. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts. Immunobiology 2013;218:1227-34. [PMID: 23706599 DOI: 10.1016/j.imbio.2013.04.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
37 Erturk A, Cure E, Cure M, Parlak E, Kurt A, Ogullar S. The association between serum YKL-40 levels, mean platelet volume, and c-reactive protein in patients with cellulitis. Indian Journal of Medical Microbiology 2015;33:S61-6. [DOI: 10.4103/0255-0857.150891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
38 Nøjgaard C, Høst NB, Christensen IJ, Poulsen SH, Egstrup K, Price PA, Johansen JS. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 2008;19:257-63. [PMID: 18480670 DOI: 10.1097/MCA.0b013e3282f40dd5] [Cited by in Crossref: 72] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
39 Prakash M, Bodas M, Prakash D, Nawani N, Khetmalas M, Mandal A, Eriksson C. Diverse pathological implications of YKL-40: Answers may lie in ‘outside-in’ signaling. Cellular Signalling 2013;25:1567-73. [DOI: 10.1016/j.cellsig.2013.03.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 6.6] [Reference Citation Analysis]